Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (401-410 of 583) with videos related to

Pageof 59
Sort By:
Blood|May 31, 2012
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instabilityLiran I Shlush, Noa Chapal-Ilani, Rivka Adar, et al.
Cancer Research|October 28, 2016
Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole AbnormalityAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Leukemia|March 13, 2019
Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cellsMarius Bill, Dimitrios Papaioannou, Malith Karunasiri, et al.
Blood|July 27, 2001
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone, D T Berg, S L George, et al.
Blood|May 9, 2001
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 lociL J Rush, Z Dai, D J Smiraglia, et al.
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformationAnn-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Leukemia|August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutationsAlice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Pageof 59

Showing results (401-410 of 583) with videos related to

Sort By:
Pageof 59
Blood|May 31, 2012
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instabilityLiran I Shlush, Noa Chapal-Ilani, Rivka Adar, et al.
Cancer Research|October 28, 2016
Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole AbnormalityAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Leukemia|March 13, 2019
Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cellsMarius Bill, Dimitrios Papaioannou, Malith Karunasiri, et al.
Blood|July 27, 2001
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineR M Stone, D T Berg, S L George, et al.
Blood|May 9, 2001
Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 lociL J Rush, Z Dai, D J Smiraglia, et al.
Cancer|January 15, 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, L A Leone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformationAnn-Kathrin Eisfeld, Sebastian Schwind, Kevin W Hoag, et al.
Leukemia|August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutationsAlice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Sherif S Farag, Stephen L George, Edward J Lee, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Pageof 59